SBI Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested).
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Equity | 98.29% |
| Cash & Equivalents | 1.65% |
| Treasury Bills | 0.05% |
Click a sector to filter the holdings below (holdings map to our sector list where the company is known).
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 12.72% | 1.01 pp | 146.5 |
| Divi's Laboratories Ltd | Healthcare | 7.46% | 0.69 pp | 83.9 |
| Acutaas Chemicals Ltd | Healthcare | 5.17% | -0.23 pp | 67.6 |
| Cipla Ltd | Healthcare | 5.07% | 5.07 pp | 35.4 |
| Apollo Hospitals Enterprise Limited | Healthcare | 4.98% | -0.32 pp | 74.7 |
| Torrent Pharmaceuticals Ltd | Healthcare | 4.74% | 1.26 pp | 78.2 |
| Max Healthcare Institute Limited | Healthcare | 4.58% | -0.59 pp | 126.0 |
| Laurus Labs Ltd | Healthcare | 4.04% | 0.98 pp | 122.5 |
| Aurobindo Pharma Ltd | Healthcare | 3.86% | 0.65 pp | 37.4 |
| Aster Dm Quality Care Ltd | Healthcare | 3.65% | -0.24 pp | 207.5 |
| Biocon Limited | Healthcare | 2.96% | -0.16 pp | 597.3 |
| Jupiter Life Line Hospitals Ltd | Healthcare | 2.88% | 0.33 pp | 9.0 |
| Anthem Biosciences Limited | Healthcare | 2.82% | -0.63 pp | 77.2 |
| Gland Pharma Ltd | Healthcare | 2.78% | 0.35 pp | 34.3 |
| Fortis Healthcare Ltd | Healthcare | 2.63% | -0.58 pp | 257.5 |
| TREPS | — | 2.56% | -0.11 pp | — |
| Sai Life Sciences Limited | Healthcare | 2.44% | -0.04 pp | 90.6 |
| Aether Industries Limited | Chemicals | 2.28% | -1.07 pp | 123.9 |
| Sudeep Pharma Ltd | Chemicals | 2.22% | -0.01 pp | 115.9 |
| Poly Medicure Limited | Healthcare | 2.02% | -0.22 pp | 50.5 |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 1.98% | -0.48 pp | 111.2 |
| Ajanta Pharma Limited | Healthcare | 1.93% | -0.03 pp | 44.9 |
| Concord Biotech Ltd | Healthcare | 1.89% | -0.01 pp | 51.0 |
| Mankind Pharma Ltd | Healthcare | 1.83% | -1.50 pp | 47.4 |
| Lupin Limited | Healthcare | 1.79% | -2.05 pp | 13.3 |
| Cohance Lifesciences Ltd | Healthcare | 1.73% | 0.61 pp | 95.7 |
| Global Health Ltd | Healthcare | 1.67% | 1.67 pp | 76.2 |
| Nephrocare Health Services Ltd | Healthcare | 1.20% | 0.22 pp | — |
| Dr. Lal PathLabs Ltd | Healthcare | 1.06% | 1.06 pp | 38.7 |
| Abbott India Ltd | Healthcare | 1.03% | -0.44 pp | 35.7 |
| Syngene International Ltd | Healthcare | 0.96% | 0.96 pp | 64.2 |
| Rainbow Children's Medicare Ltd | Healthcare | 0.85% | -0.02 pp | 53.1 |
| Healthcare Global Enterprises Limited | Healthcare | 0.73% | 0.73 pp | 569.3 |
| Gufic Biosciences Ltd | Healthcare | 0.36% | -0.10 pp | 58.9 |
| 364 DAY T-BILL 19.11.26 | — | 0.05% | -0.01 pp | — |
Expense ratio by month: Oct 25 0.91% · Nov 25 0.91% · Dec 25 0.91% · Jan 26 0.92% · Feb 26 0.91% · Mar 26 0.92% · Apr 26 0.92% · May 26 0.91% · Jun 26 1.03% · Jul 26 1.02% · Aug 26 1.04% · Sep 26 1.03%
The scheme information document (exit load, minimum investment, fund managers, objective, benchmark, riskometer) is not loaded for this fund yet.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
